A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

NCT07539415 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of the experimental drug DWRX5003 and how well it is absorbed in the body compared to two other drugs (DWC202502 and DWC202503) in healthy adults.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 72 people Planned (estimated).

Who can join Ages 19–64 · all sexes Healthy volunteers accepted.

Timeline Started 2026-03 · est. completion 2026-08

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT07539415 ↗

Description as written by the study sponsor.

Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults

Treatments tested

DWRX5003 Drug

Microneedle patch containing Semaglutide
DWC202502 Drug

Semagluide
DWC202503 Drug

Semaglutide
DWRX5003P Other

placebo microneedle patch

Main thing measured	AUC 0-t
Sponsor	Daewoong Pharmaceutical Co. LTD.
Conditions studied	Obesity & Overweight, Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07539415 ↗